1. Metabolic Enzyme/Protease
  2. Cytochrome P450
  3. Methoxsalen

キサントトキシン  (Synonyms: Methoxsalen; 8-Methoxypsoralen; Xanthotoxin; 8-MOP)

製品番号: HY-30151 純度: 99.97%
COA 取扱説明書 Technical Support

Methoxsalen (8-Methoxypsoralen) is a furanocoumarin compound used in psoralen, used in studies of psoriasis, eczema, vitiligo and some sun-exposed cutaneous lymphomas, and is a P450 inhibitor.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 298-81-7

容量 価格(税別) 在庫状況 数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 60 在庫あり
Solution
10 mM * 1 mL in DMSO USD 60 在庫あり
Solid
500 mg $55 在庫あり
1 g $79 在庫あり
5 g $135 在庫あり
10 g $220 在庫あり
25 g $350 在庫あり
50 g $490 在庫あり
> 100 g   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 17 publication(s) in Google Scholar

Other Forms of Methoxsalen:

Top Publications Citing Use of Products

    Methoxsalen purchased from MedChemExpress. Usage Cited in: Insect Biochem Mol Biol. 2022 Jul:146:103796.  [Abstract]

    Qualitative enzyme activities to Methoxsalen (xanthotoxin) with six recombinant mutants.

    Methoxsalen purchased from MedChemExpress. Usage Cited in: Clin Chem. 2019 Dec;65(12):1522-1531.  [Abstract]

    Top-ranked ingredients associated with false positives on the amphetamines and buprenorphine screens.

    Methoxsalen purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Nov 16;9(1):4820.  [Abstract]

    Compared with the SCD strain, LC50 values were significantly decreased to Methoxsalen (xanthotoxin, 4.1-fold) and 2-tridecanone (1.4-fold) in the knockout SCD-d6AE strain.

    Methoxsalen purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Nov 16;9(1):4820.  [Abstract]

    Metabolism of Methoxsalen (xanthotoxin), 2-tridecanone, and indoxacarb by recombinant P450s. CYP6AE subfamily enzymes were from H. armigera and CYP6B1 from Papilio polyxenes. Error bars represent mean values ± SEM (n = 4). Asterisk indicates that no significant metabolism was detected (limits of detection were 0.081, 0.033, and 0.016 pmol/min/pmol P450 for Methoxsalen (xanthotoxin), 2-tridecanone, and indoxacarb, respectively).

    Methoxsalen purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Nov 16;9(1):4820.  [Abstract]

    The results showed that the CYP6AE19 and CYP6AE20 transcripts (>1000-fold induction in midgut and >100-fold induction in fat body) are very strongly induced by Methoxsalen (xanthotoxin). Furthermore, CYP6AE14 transcripts are induced in midgut (40-fold) after dietary exposure to gossypol.
    • 生物活性

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Methoxsalen (8-Methoxypsoralen) is a furanocoumarin compound used in psoralen, used in studies of psoriasis, eczema, vitiligo and some sun-exposed cutaneous lymphomas, and is a P450 inhibitor.

    Cellular Effect
    Cell Line Type Value Description References
    A-431 IC50
    >30 μM
    Compound: 8-MOP
    Antiproliferative activity against human A431 cells after 24 hrs by trypan blue dye assay
    Antiproliferative activity against human A431 cells after 24 hrs by trypan blue dye assay
    [PMID: 22537681]
    A-431 IC50
    2.48 μM
    Compound: 8-MOP
    Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound
    Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound
    [PMID: 8893844]
    A-431 IC50
    25 μM
    Compound: 8-MOP
    Antiproliferative activity against human A431 cells incubated for 1 hr with inhibitor followed by UV irradiation measured after 24 hrs by trypan blue dye assay
    Antiproliferative activity against human A431 cells incubated for 1 hr with inhibitor followed by UV irradiation measured after 24 hrs by trypan blue dye assay
    [PMID: 22537681]
    AGS IC50
    >100 μM
    Compound: Xanthotoxin
    Anti-proliferative activity against human AGS cells after 48 hrs by MTT assay
    Anti-proliferative activity against human AGS cells after 48 hrs by MTT assay
    [PMID: 28947149]
    HCT-116 IC50
    >100 μM
    Compound: 6
    Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
    [PMID: 23746477]
    HeLa IC50
    >20 μM
    Compound: 8 -MOP
    Antiproliferative activity against HeLa (human cervix adenocarcinoma cells) in dark condition
    Antiproliferative activity against HeLa (human cervix adenocarcinoma cells) in dark condition
    [PMID: 12930143]
    HeLa IC50
    >20 μM
    Compound: 8-MOP
    The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the dark
    The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the dark
    [PMID: 10543884]
    HeLa IC50
    >20 μM
    Compound: 8-MOP
    Antiproliferative activity against HeLa cells in dark
    Antiproliferative activity against HeLa cells in dark
    [PMID: 16821791]
    HeLa IC50
    >20 μM
    Compound: 8-MOP
    Photo-antiproliferative activity against human HeLa cells under dark condition
    Photo-antiproliferative activity against human HeLa cells under dark condition
    [PMID: 19359172]
    HeLa IC50
    >30 μM
    Compound: 8-MOP
    Antiproliferative activity against human HeLa cells after 24 hrs by trypan blue dye assay
    Antiproliferative activity against human HeLa cells after 24 hrs by trypan blue dye assay
    [PMID: 22537681]
    HeLa IC50
    10 μM
    Compound: 8-MOP
    Antiproliferative activity against human HeLa cells incubated for 1 hr with inhibitor followed by UV irradiation measured after 24 hrs by trypan blue dye assay
    Antiproliferative activity against human HeLa cells incubated for 1 hr with inhibitor followed by UV irradiation measured after 24 hrs by trypan blue dye assay
    [PMID: 22537681]
    HeLa IC50
    10 mM
    Compound: 8-MOP (8-Methoxypsoralen)
    In vitro antiproliferative activity against human cervix adenocarcinoma (HeLa) cells
    In vitro antiproliferative activity against human cervix adenocarcinoma (HeLa) cells
    [PMID: 10673096]
    HeLa IC50
    10 μM
    Compound: 8 -MOP
    Antiproliferative activity against HeLa (human cervix adenocarcinoma cells) after exposure to UV light
    Antiproliferative activity against HeLa (human cervix adenocarcinoma cells) after exposure to UV light
    [PMID: 12930143]
    HeLa IC50
    10 μM
    Compound: 8-MOP
    The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the presence of UVA(ultra violet A irradiated)
    The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the presence of UVA(ultra violet A irradiated)
    [PMID: 10543884]
    HeLa IC50
    10 μM
    Compound: 8-MOP
    Compound was evaluated for its antiproliferative activity after UVA irradiation on human tumor HeLa cell line
    Compound was evaluated for its antiproliferative activity after UVA irradiation on human tumor HeLa cell line
    [PMID: 11965365]
    HeLa IC50
    10 μM
    Compound: 8-MOP
    Antiproliferative activity against HeLa cells in presence of 0.789 J/cm2 UVA light
    Antiproliferative activity against HeLa cells in presence of 0.789 J/cm2 UVA light
    [PMID: 16821791]
    HeLa IC50
    10 μM
    Compound: 8-MOP
    Photo-antiproliferative activity against human HeLa cells exposed to 365 nm, 0.793 Jcm'-2 UVA light
    Photo-antiproliferative activity against human HeLa cells exposed to 365 nm, 0.793 Jcm'-2 UVA light
    [PMID: 19359172]
    HeLa IC50
    3.16 μM
    Compound: 8-MOP
    Compound was evaluated for cell growth inhibition against HeLa cell line by irradiation in the presence of examined compound
    Compound was evaluated for cell growth inhibition against HeLa cell line by irradiation in the presence of examined compound
    [PMID: 8893844]
    HeLa IC50
    7.6 μg/mL
    Compound: Xanthotoxin
    Antitumor activity against human HeLa cells after 72 hrs by MTS assay
    Antitumor activity against human HeLa cells after 72 hrs by MTS assay
    [PMID: 19217697]
    HL-60 IC50
    >20 μM
    Compound: 8-MOP
    Cytotoxicity against human HL60 cells treated under dark condition after 24 hrs by trypan blue assay
    Cytotoxicity against human HL60 cells treated under dark condition after 24 hrs by trypan blue assay
    [PMID: 20615713]
    HL-60 IC50
    >20 μM
    Compound: 8-MOP
    Cytotoxicity against human HL60 cells treated under dark condition after 72 hrs by trypan blue assay
    Cytotoxicity against human HL60 cells treated under dark condition after 72 hrs by trypan blue assay
    [PMID: 20615713]
    HL-60 IC50
    >20 μM
    Compound: 8 -MOP
    Antiproliferative activity against HL-60 (human promyelocytic leukemic cells) in dark condition
    Antiproliferative activity against HL-60 (human promyelocytic leukemic cells) in dark condition
    [PMID: 12930143]
    HL-60 IC50
    >20 μM
    Compound: 8-MOP
    The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the dark
    The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the dark
    [PMID: 10543884]
    HL-60 IC50
    >20 μM
    Compound: 8-MOP
    Antiproliferative activity against HL60 cells in dark
    Antiproliferative activity against HL60 cells in dark
    [PMID: 16821791]
    HL-60 IC50
    0.75 μM
    Compound: 8-MOP
    Compound was evaluated for cell growth inhibition against HL 60 cell line by irradiation in the presence of examined compound
    Compound was evaluated for cell growth inhibition against HL 60 cell line by irradiation in the presence of examined compound
    [PMID: 8893844]
    HL-60 IC50
    1.2 μM
    Compound: 8-MOP
    Photocytotoxicity against human HL-60 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
    Photocytotoxicity against human HL-60 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
    [PMID: 18951030]
    HL-60 IC50
    1.2 μM
    Compound: 8-MOP
    Cytotoxicity against HL-60 (human fibrosarcoma) cell line at 3.2 joule/cm**2 UVA dose
    Cytotoxicity against HL-60 (human fibrosarcoma) cell line at 3.2 joule/cm**2 UVA dose
    [PMID: 15837311]
    HL-60 IC50
    1.4 μM
    Compound: 8-MOP
    Photocytotoxicity against human HL-60 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
    Photocytotoxicity against human HL-60 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
    [PMID: 18951030]
    HL-60 IC50
    1.4 μM
    Compound: 8-MOP
    Cytotoxicity against HL-60 (human fibrosarcoma) cell line at 2.5 joule/cm**2 UVA dose
    Cytotoxicity against HL-60 (human fibrosarcoma) cell line at 2.5 joule/cm**2 UVA dose
    [PMID: 15837311]
    HL-60 IC50
    5.4 μM
    Compound: 8-MOP
    Cytotoxicity against human HL60 cells after 24 hrs by trypan blue assay in presence of 0.789 J cm-2 of UVA light
    Cytotoxicity against human HL60 cells after 24 hrs by trypan blue assay in presence of 0.789 J cm-2 of UVA light
    [PMID: 20615713]
    HL-60 IC50
    5.4 mM
    Compound: 8-MOP (8-Methoxypsoralen)
    In vitro antiproliferative activity against human promyelocytic (HL-60) cells
    In vitro antiproliferative activity against human promyelocytic (HL-60) cells
    [PMID: 10673096]
    HL-60 IC50
    5.4 μM
    Compound: 8 -MOP
    Antiproliferative activity against HL-60 (human promyelocytic leukemic cells) after exposure to UV light
    Antiproliferative activity against HL-60 (human promyelocytic leukemic cells) after exposure to UV light
    [PMID: 12930143]
    HL-60 IC50
    5.4 μM
    Compound: 8-MOP
    The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the presence of UVA(ultra violet A irradiated)
    The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the presence of UVA(ultra violet A irradiated)
    [PMID: 10543884]
    HL-60 IC50
    5.4 μM
    Compound: 8-MOP
    Compound was evaluated for its antiproliferative activity after UVA irradiation on human tumor HL-60 cell line
    Compound was evaluated for its antiproliferative activity after UVA irradiation on human tumor HL-60 cell line
    [PMID: 11965365]
    HL-60 IC50
    5.4 μM
    Compound: 8-MOP
    Antiproliferative activity against HL60 cells in presence of 0.789 J/cm2 UVA light
    Antiproliferative activity against HL60 cells in presence of 0.789 J/cm2 UVA light
    [PMID: 16821791]
    HT-1080 IC50
    1.5 μM
    Compound: 8-MOP
    Inhibition of cell growth after irradiation at UVA dose of 6.5 J/cmE-2 in HT1080 human fibrosarcoma cell line
    Inhibition of cell growth after irradiation at UVA dose of 6.5 J/cmE-2 in HT1080 human fibrosarcoma cell line
    [PMID: 12873520]
    HT-1080 IC50
    1.9 μM
    Compound: 8-MOP
    Photocytotoxicity against human HT1080 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
    Photocytotoxicity against human HT1080 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
    [PMID: 18951030]
    HT-1080 IC50
    2.1 μM
    Compound: 8-MOP
    Inhibition of cell growth after irradiation at UVA dose of 3.2 J/cmE-2 in HT1080 human fibrosarcoma cell line
    Inhibition of cell growth after irradiation at UVA dose of 3.2 J/cmE-2 in HT1080 human fibrosarcoma cell line
    [PMID: 12873520]
    HT-1080 IC50
    7.8 μM
    Compound: 8-MOP
    Inhibition of cell growth after irradiation at UVA dose of 2.6 J/cmE-2 in HT1080 human fibrosarcoma cell line
    Inhibition of cell growth after irradiation at UVA dose of 2.6 J/cmE-2 in HT1080 human fibrosarcoma cell line
    [PMID: 12873520]
    HT-1080 IC50
    7.8 μM
    Compound: 8-MOP
    Photocytotoxicity against human HT1080 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
    Photocytotoxicity against human HT1080 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
    [PMID: 18951030]
    HT-29 IC50
    >100 μM
    Compound: 6
    Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay
    [PMID: 23746477]
    Jurkat IC50
    >20 μM
    Compound: 8MOP
    Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay
    Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay
    [PMID: 19230658]
    Jurkat IC50
    1.2 μM
    Compound: 8MOP
    Phototoxicity against human Jurkat cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay
    Phototoxicity against human Jurkat cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay
    [PMID: 19230658]
    Jurkat IC50
    1.2 μM
    Compound: 8-MOP
    Photocytotoxicity against human JURKAT cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
    Photocytotoxicity against human JURKAT cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
    [PMID: 18951030]
    K562 IC50
    >20 μM
    Compound: 8MOP
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    [PMID: 19230658]
    L02 IC50
    >100 μM
    Compound: Xanthotoxin
    Anti-proliferative activity against human L02 cells after 48 hrs by MTT assay
    Anti-proliferative activity against human L02 cells after 48 hrs by MTT assay
    [PMID: 28947149]
    LoVo IC50
    >20 μM
    Compound: 8MOP
    Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
    Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
    [PMID: 19230658]
    LoVo IC50
    0.4 μM
    Compound: 8-MOP
    Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 6.5 joule/cm**2 UVA dose
    Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 6.5 joule/cm**2 UVA dose
    [PMID: 15837311]
    LoVo IC50
    0.7 μM
    Compound: 8MOP
    Phototoxicity against human LoVo cells exposed to irradiation with 3.75 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay
    Phototoxicity against human LoVo cells exposed to irradiation with 3.75 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay
    [PMID: 19230658]
    LoVo IC50
    0.7 μM
    Compound: 8-MOP
    Photocytotoxicity against human LoVo cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
    Photocytotoxicity against human LoVo cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
    [PMID: 18951030]
    LoVo IC50
    0.7 μM
    Compound: 8-MOP
    Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 3.2 joule/cm**2 UVA dose
    Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 3.2 joule/cm**2 UVA dose
    [PMID: 15837311]
    LoVo IC50
    1.1 μM
    Compound: 8MOP
    Phototoxicity against human LoVo cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay
    Phototoxicity against human LoVo cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay
    [PMID: 19230658]
    LoVo IC50
    1.1 μM
    Compound: 8-MOP
    Photocytotoxicity against human LoVo cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
    Photocytotoxicity against human LoVo cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
    [PMID: 18951030]
    LoVo IC50
    1.1 μM
    Compound: 8-MOP
    Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 2.5 joule/cm**2 UVA dose
    Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 2.5 joule/cm**2 UVA dose
    [PMID: 15837311]
    MES-SA/Dx5 IC50
    3.1 μM
    Compound: 6
    Cytotoxicity against human MES-SA/Dx5 cells after 96 hrs by MTT assay
    Cytotoxicity against human MES-SA/Dx5 cells after 96 hrs by MTT assay
    [PMID: 23746477]
    NCTC-2544 IC50
    >20 μM
    Compound: 8MOP
    Cytotoxicity against human NCTC-2544 cells after 72 hrs by MTT assay
    Cytotoxicity against human NCTC-2544 cells after 72 hrs by MTT assay
    [PMID: 19230658]
    NCTC-2544 IC50
    0.9 μM
    Compound: 8-MOP
    Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
    Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
    [PMID: 18951030]
    NCTC-2544 IC50
    5.5 μM
    Compound: 8MOP
    Phototoxicity against human NCTC-2544 cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay
    Phototoxicity against human NCTC-2544 cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay
    [PMID: 19230658]
    NCTC-2544 IC50
    5.5 μM
    Compound: 8-MOP
    Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
    Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
    [PMID: 18951030]
    PAM212 IC50
    >100 μM
    Compound: 2; 8-MOP
    Dark toxicity against mouse PAM212 cells assessed as cell growth inhibition incubated for 30 mins under dark condition measured after 5 days by coulter counting method
    Dark toxicity against mouse PAM212 cells assessed as cell growth inhibition incubated for 30 mins under dark condition measured after 5 days by coulter counting method
    [PMID: 30638875]
    PAM212 IC50
    >100 μM
    Compound: 2; 8-MOP
    Dark toxicity against mouse PAM212 cells assessed as cell growth inhibition incubated for 5 days under dark condition by coulter counting method
    Dark toxicity against mouse PAM212 cells assessed as cell growth inhibition incubated for 5 days under dark condition by coulter counting method
    [PMID: 30638875]
    PAM212 IC50
    0.1 μM
    Compound: 2; 8-MOP
    Phototoxicity against mouse PAM212 cells assessed as cell growth inhibition preincubated for 30 mins followed by 1.28 J/cm2 UV light exposure and measured after 5 days by coulter counting method
    Phototoxicity against mouse PAM212 cells assessed as cell growth inhibition preincubated for 30 mins followed by 1.28 J/cm2 UV light exposure and measured after 5 days by coulter counting method
    [PMID: 30638875]
    PANC-1 IC50
    83.3 μM
    Compound: 6
    Cytotoxicity against human PANC1 cells after 96 hrs by MTT assay
    Cytotoxicity against human PANC1 cells after 96 hrs by MTT assay
    [PMID: 23746477]
    Panel leukemia (Carcinoma cell lines) IC50
    >100 μM
    Compound: 1
    In vitro photocytotoxicity is evaluated against human chronic myeloid leukemia cells grown in culture under the dark conditions
    In vitro photocytotoxicity is evaluated against human chronic myeloid leukemia cells grown in culture under the dark conditions
    [PMID: 8164263]
    Panel leukemia (Carcinoma cell lines) IC50
    100 μM
    Compound: 1
    In vitro photocytotoxicity is evaluated against human chronic myeloid leukemia cells grown in culture irradiated at 366 nM
    In vitro photocytotoxicity is evaluated against human chronic myeloid leukemia cells grown in culture irradiated at 366 nM
    [PMID: 8164263]
    Raji IC50
    490 molar ratio
    Compound: 7
    Inhibition of TPA-induced EBV-early antigen activation in human Raji cells
    Inhibition of TPA-induced EBV-early antigen activation in human Raji cells
    [PMID: 16441065]
    体内実験

    Methoxsalen (15mg/kg, i.p, single dose) increases nicotine’s Cmax prolongs the plasma nicotine half-life (fourfold increase), decreases its clearance (sixfold decrease), and increases its AUC[1].
    Methoxsalen (15mg/kg, i.p, single dose) enhances the potency of pharmacological effects of oral nicotine (i.e., body temperature and analgesia)[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male adult ICR mice[1]
    Dosage: 15 mg/kg
    Administration: Intraperitoneal injection (i.p.), single dose
    Result: Increased nicotine plasma levels were still above 10ng/ml at 6hr.
    Induced nicotine’s antinociceptive and hypothermic lasted close to 6 and 24 hr.
    臨床実験
    分子量

    216.19

    分子式

    C12H8O4

    CAS 番号
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    O=C1OC(C(C=C1)=C2)=C(OC)C3=C2C=CO3

    Structure Classification
    Initial Source
    輸送条件

    Room temperature in continental US; may vary elsewhere.

    保管条件
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    溶剤 & 溶解度
    体外: 

    DMSO : 50 mg/mL (231.28 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : < 0.1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.6256 mL 23.1278 mL 46.2556 mL
    5 mM 0.9251 mL 4.6256 mL 9.2511 mL
    10 mM 0.4626 mL 2.3128 mL 4.6256 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます:C1V1 = C2V2

    濃度 (開始)

    C1

    ×
    体積 (開始)

    V1

    =
    濃度 (終了)

    C2

    ×
    体積 (終了)

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (11.56 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (11.56 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    純度とドキュメンテーション

    純度: 99.98%

    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 4.6256 mL 23.1278 mL 46.2556 mL 115.6390 mL
    5 mM 0.9251 mL 4.6256 mL 9.2511 mL 23.1278 mL
    10 mM 0.4626 mL 2.3128 mL 4.6256 mL 11.5639 mL
    15 mM 0.3084 mL 1.5419 mL 3.0837 mL 7.7093 mL
    20 mM 0.2313 mL 1.1564 mL 2.3128 mL 5.7820 mL
    25 mM 0.1850 mL 0.9251 mL 1.8502 mL 4.6256 mL
    30 mM 0.1542 mL 0.7709 mL 1.5419 mL 3.8546 mL
    40 mM 0.1156 mL 0.5782 mL 1.1564 mL 2.8910 mL
    50 mM 0.0925 mL 0.4626 mL 0.9251 mL 2.3128 mL
    60 mM 0.0771 mL 0.3855 mL 0.7709 mL 1.9273 mL
    80 mM 0.0578 mL 0.2891 mL 0.5782 mL 1.4455 mL
    100 mM 0.0463 mL 0.2313 mL 0.4626 mL 1.1564 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます:C1V1 = C2V2

    濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

     

    カスタマ需要量 *

    お名前 *

     

    タイトル

    メールアドレス *

     

    電話番号 *

    デパートメント

     

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

         

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Methoxsalen
    製品番号:
    HY-30151
    数量:
    MCE 日本正規代理店: